10 November, 2023: Frontier Biotechnologies Inc. (Frontier Biotech) has partnered with Keyuan Xinhai (Beijing) Medical Products, to introduce GANCIL^® (Valganciclovir Hydrochloride Tablets), a groundbreaking treatment option for cytomegalovirus (CMV) infection in China. This collaboration marks a significant milestone in the medical landscape, offering hope to countless adults battling HIV and organ transplant recipients on the brink of CMV infection.

The introduction of GANCIL^® promises to revolutionize the management of CMV infection. This relentless virus has posed a significant challenge for individuals living with HIV, as well as those who have undergone organ transplants. GANCIL^®, a cutting-edge antiviral medication, has shown remarkable efficacy in inhibiting the replication of the CMV virus, providing a ray of hope for patients burdened by this debilitating infection.

By joining forces with Keyuan Xinhai Medical Products, Frontier Biotechnologies aims to ensure the widespread availability of Gancil across the nation. This strategic partnership combines Frontier Biotechnologies' expertise in biotechnology with Xinhai Medical Products' extensive network and commitment to delivering high-quality healthcare solutions. Together, they are poised to make a profound impact on the lives of patients grappling with CMV infection.

This innovative treatment option has the potential to transform the lives of countless individuals battling CMV infection. 

In January 2023, the National Medicine Products Administration approved

Valganciclovir Hydrochloride Tablets (Trade name: GANCIL^®). The first shipment

arrived at Beijing port on 7 October, 2023.